<DOC>
	<DOCNO>NCT02419521</DOCNO>
	<brief_summary>The purpose trial ass safety efficacy Resolute Onyx Zotarolimus-Eluting Coronary Stent System treatment de novo lesion native coronary artery reference vessel diameter 2.25 mm 4.2 mm .</brief_summary>
	<brief_title>Medtronic Resolute Onyx Core ( 2.25 mm - 4.0 mm ) Clinical Study</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Must acceptable candidate percutaneous coronary intervention ( PCI ) , stenting , emergent coronary artery bypass graft ( CABG ) surgery Must clinical evidence ischemic heart disease , stable unstable angina , and/or positive functional study Must require treatment either ) single target lesion amenable treatment OR b ) two target lesion locate separate target vessel Target lesion ( ) must de novo lesion ( ) native coronary artery ( y ) Known hypersensitivity contraindication aspirin , heparin bivalirudin , thienopyridines , cobalt , nickel , platinum , iridium , chromium , molybdenum , polymer coating ( e.g . BioLinx ) sensitivity contrast medium , adequately premedicated History allergic reaction significant sensitivity drug zotarolimus , rapamycin , tacrolimus , everolimus , analogue derivative History stroke transient ischemic attack ( TIA ) within prior 6 month Active peptic ulcer upper gastrointestinal ( GI ) bleeding within prior 6 month History bleed diathesis coagulopathy refuse blood transfusion Concurrent medical condition life expectancy le 12 month Currently participate investigational drug another device trial complete primary endpoint Documented leave ventricular ejection fraction ( LVEF ) &lt; 30 % recent evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>